Marwan Fakih
City Of Hope National Medical Center · 726 works · 28,345 citations · h-index 72
Top works
- Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study
- The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
- KRAS G12C Inhibition with Sotorasib in Advanced Solid Tumors
- Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials
- Colon Cancer
- Rectal Cancer
- Gastric Cancer, Version 2.2013
- Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer
- Metastatic Colorectal Cancer: Current State and Future Directions
- Treatment of Metastatic Colorectal Cancer: ASCO Guideline
- Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study
- Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer
- Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial
- Geriatric Assessment–Driven Intervention (GAIN) on Chemotherapy-Related Toxic Effects in Older Adults With Cancer
- Glucocorticoids and treatment of prostate cancer: a preclinical and clinical review
- Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial
- Phase I and Pharmacokinetic Study of Sorafenib in Patients With Hepatic or Renal Dysfunction: CALGB 60301
- Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With BRAF V600E–Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study
- Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C
- Rectal Cancer